Hospira (HSP) Enrolls First Patient in Biosimilar EPO Phase III
Down)
Hospira, Inc. (NYSE: HSP), has announced enrollment of the first patient in a Phase III U.S. clinical program for its biosimilar erythropoietin (EPO).
Hospira's Phase III program, which follows a successful Phase I trial that concluded last year, will compare safety and efficacy of Hospira's EPO and the reference product, Amgen's Epogen® in patients with renal (kidney) dysfunction who have anemia. Erythropoietin is a treatment for anemia associated with chronic renal failure.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Hospira's Phase III program, which follows a successful Phase I trial that concluded last year, will compare safety and efficacy of Hospira's EPO and the reference product, Amgen's Epogen® in patients with renal (kidney) dysfunction who have anemia. Erythropoietin is a treatment for anemia associated with chronic renal failure.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Cytokinetics (CYTK) Opens Second Cohort for ATOMIC-AHF Phase IIb
- Repros Therapeutics (RPRX) Modifies Pivotal Androxal Protocol
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
